Phosphatidylinositol phosphate kinase type 1 gamma splice variants as biomarkers and drug targets for epithelial cancers
AssigneeWisconsin Alumni Research Foundation
InventorsRichard A. Anderson, Nicholas J. Schill
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to the field of phosphatidylinositol based signaling pathways, and more specifically to the use of novel members of these pathways for disease prognosis and treatment. In some aspects, the present invention relates to the use of novel splice variants of type I phosphatidylinositol phosphate kinase γ, named PIPKIγ 700 and PIPKIγ 707, to determine breast cancer and breast cancer prognosis.
Claims16
-35. (canceled)
An isolated polynucleotide encoding a polypeptide having lipid kinase activity, wherein the polynucleotide comprises a sequence selected from the group consisting of:
- a) a polynucleotide sequence encoding an amino acid sequence having at least about 95% sequence identity to SEQ ID NO:
- 4;
- b) a polynucleotide sequence comprising SEQ ID NO:
- 2;
- c) a polynucleotide sequence which is fully complementary to the polynucleotides of (a) or (b).
A method for prognostic evaluation of a patient comprising:
- a) detecting a nucleic acid molecule comprising SEQ ID NO:
- 2 in a tissue sample from a patient having, suspected of having, or at risk of developing breast cancer;
- b) comparing the results of step (a) with an amount of the same sequence detected in a control sample;
- and
- c) evaluating the prognosis of the patient based on the comparison of step (b), wherein a lower amount of the detected sequence compared to the amount detected in the control sample indicates a better prognosis, and wherein an equal or higher amount of the detected sequence compared to the amount detected in the control sample indicates a poor prognosis.
A method for identifying an agent that modulates the activity of phosphatidylinositol phosphate kinase gamma 707 (PIPKIγ 707) comprising:
- a) contacting the PIPKIγ 707 with the agent in the presence of LMO4;
- and
- b) determining whether the agent modulates the activity or localization of LMO4 as compared to a control, wherein a change in the activity or localization of LMO4 as compared to the control is indicative of the agent modulating PIPKIγ 707 activity.
Dependencies are inferred from the claim text.